31 August 2014 - Takis co-authors an Oncotarget article describing a novel, aerosol-mediated antibody delivery platform

Takis is happy to announce the publication of the article "Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab" appeared on Oncotarget and co-authored by Takis' researchers.

Luigi Aurisicchio, CEO/CSO at Takis: "As scientists, we are more than happy to contribute to important scientific and technology achievements, like the platform perfectioned and described by our Sigma-Tau collaborators in Oncotarget".

For more info: http://www.ncbi.nlm.nih.gov/pubmed/25238453

cover issue 76 en US